51 – 60 of 62
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
(
- Contribution to journal › Article
-
Mark
Incidence of and risk factors for neonatal morbidity after active perinatal care: extremely preterm infants study in Sweden (EXPRESS)
(
- Contribution to journal › Article
- 2009
-
Mark
Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities
(
- Contribution to journal › Published meeting abstract
-
Mark
One-Year Survival of Extremely Preterm Infants After Active Perinatal Care in Sweden
(
- Contribution to journal › Article
- 2008
-
Mark
Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy
(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
Concurrent gain of 17q and the MYC oncogene in a medullomyoblastoma
(
- Contribution to journal › Article
-
Mark
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients
(
- Contribution to journal › Article
-
Mark
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following Myelodysplastic syndrome
(
- Contribution to journal › Article
- 2006
-
Mark
A pharmacodynamic study of 5-azacytidine in the P39 cell line
(
- Contribution to journal › Article
-
Mark
How do Swedish paediatric clinics diagnose coeliac disease? Results of a nationwide questionnaire study
(
- Contribution to journal › Article